Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB

Di Liu; Fang Jie; Yongjie Ding; Hongping Qu; Dechang Chen; Jie Huang

doi:10.3855/jidc.18887

Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB

Authors

Di Liu Department of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China
Fang Jie Department of Pharmacy, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China
Yongjie Ding Department of Respiratory and Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China
Hongping Qu Department of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China
Dechang Chen Department of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China
Jie Huang Department of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China https://orcid.org/0000-0001-7003-5725

DOI:

https://doi.org/10.3855/jidc.18887

Keywords:

polymyxin, colistin sulfate, polymyxin B sulfate, carbapenem-resistant Gram-negative bacteria, pneumonia

Abstract

Introduction: The aim of this study was to compare the efficacy and safety of colistin sulfate (CS) with polymyxin B sulfate (PMB) in the treatment of pneumonia induced by carbapenem-resistant Gram-negative bacteria (CR-GNB).

Methodology: Patients diagnosed with pneumonia caused by CR-GNB and admitted to the intensive care unit (ICU) from January 2020 to September 2022 were enrolled in this study. The patients were divided into the CS group and the PMB group according to their medication regimens. Group-wise demographic data, clinical efficacy, prognosis, and adverse events were analyzed and compared.

Results: A total of 120 patients (68 in the CS group and 52 in the PMB group) with pneumonia were included in the study. The majority of the pathogens were CR-Acinetobacter baumannii, followed by CR-Klebsiella pneumoniae, and CR-Pseudomonas aeruginosa. The clinical response rates in the CS and PMB groups after treatment were 62.0% and 65.4%, bacterial clearances were 44.0% and 36.5%, 28-day mortality rates were 16.0% and 13.5%, respectively; no significant differences between the two treatments were found. Nevertheless, the adverse effects were significantly less common in the CS group than in the PMB group, especially when treatments were administered intravenously.

Conclusions: CS, a novel polymyxin E formulation, is as effective as PMB in treating pneumonia induced by CR-GNB while causing less side effects.

Downloads

Published

2024-07-29

How to Cite

Liu D, Jie F, Ding Y, Qu H, Chen D, Huang J (2024) Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB. J Infect Dev Ctries 18:1050–1057. doi: 10.3855/jidc.18887

Download Citation

Endnote/Zotero/Mendeley (RIS)

Issue

Vol. 18 No. 07: July 2024

Section

Original Articles

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).